dose. NOTE: In MDD clinical trials, brexpiprazole dosage was not adjusted for strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine); thus, CYP considerations are already factored into general dosing recommendations and brexpiprazole may be administered without dosage adjustment in patients with MDD.brexpiprazole and chlorpromazine both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and chlorpromazine both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and chlorpromazine both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and chlorpromazine both increase sedation. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and chlorpromazine both increase sedation. Use Caution/Monitor.buprenorphine, long-acting injectionchlorpromazine increases toxicity of buprenorphine, long-acting injection by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of buprenorphine and benzodiazepines or other CNS depressants increases risk of adverse reactions including overdose, respiratory depression, and death. Cessation of benzodiazepines or other CNS depressants is preferred in most cases. In some cases, monitoring at a higher level of care for tapering CNS depressants may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate.bupropionbupropion will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalbutabarbital and chlorpromazine both increase sedation. Use Caution/Monitor.butalbitalbutalbital and chlorpromazine both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and chlorpromazine both increase sedation. Use Caution/Monitor.caffeinechlorpromazine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.capecitabinecapecitabine and chlorpromazine both increase QTc interval. Use Caution/Monitor.carbinoxaminecarbinoxamine and chlorpromazine both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and chlorpromazine both increase sedation. Use Caution/Monitor.cenobamatecenobamate, chlorpromazine. Either increases effects of the other by sedation. Use Caution/Monitor.chloral hydratechloral hydrate and chlorpromazine both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and chlorpromazine both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.chlorzoxazonechlorzoxazone and chlorpromazine both increase sedation. Use Caution/Monitor.cigarette smokingcigarette smoking decreases levels of chlorpromazine by increasing metabolism. Use Caution/Monitor. Interaction mainly seen w/chlorpromazine & thioridazine, but may occur w/other phenothiazines.cinnarizinecinnarizine and chlorpromazine both increase sedation. Use Caution/Monitor.ciprofloxacinciprofloxacin and chlorpromazine both increase QTc interval. Use Caution/Monitor. Ciprofloxacin elicits minimal effects on QT interval. Caution if used in combination with other drugs known to affect QT interval or in patients with other risk factors.cisatracuriumcisatracurium decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cisatracurium decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of cisatracurium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.citalopramchlorpromazine and citalopram both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.clemastineclemastine and chlorpromazine both increase sedation. Use Caution/Monitor.clobazamclobazam will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. chlorpromazine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipraminechlorpromazine and clomipramine both increase sedation. Use Caution/Monitor.clonazepamclonazepam and chlorpromazine both increase sedation. Use Caution/Monitor.clonidineclonidine, chlorpromazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.clorazepateclorazepate and chlorpromazine both increase sedation. Use Caution/Monitor.clozapinechlorpromazine and clozapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and clozapine both increase sedation. Use Caution/Monitor.codeinecodeine and chlorpromazine both increase sedation. Use Caution/Monitor.chlorpromazine will decrease the level or effect of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphinecrizotinibcrizotinib and chlorpromazine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.cyclizinecyclizine and chlorpromazine both increase sedation. Use Caution/Monitor.cyclizine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.cyclizine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of cyclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclobenzaprinecyclobenzaprine and chlorpromazine both increase sedation. Use Caution/Monitor.cyclobenzaprine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyproheptadinecyproheptadine and chlorpromazine both increase sedation. Use Caution/Monitor.dabrafenibdabrafenib and chlorpromazine both increase QTc interval. Use Caution/Monitor.dantrolenedantrolene and chlorpromazine both increase sedation. Use Caution/Monitor.daridorexantchlorpromazine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.darifenacin decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.dasatinibchlorpromazine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.desfluranedesflurane and chlorpromazine both increase sedation. Use Caution/Monitor.desipraminechlorpromazine and desipramine both increase sedation. Use Caution/Monitor.desvenlafaxinedesvenlafaxine will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mgdeutetrabenazinechlorpromazine and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and chlorpromazine both increase sedation. Use Caution/Monitor.dexfenfluraminechlorpromazine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, dexfenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dexmedetomidinedexmedetomidine and chlorpromazine both increase sedation. Use Caution/Monitor.dexmethylphenidatechlorpromazine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, dexmethylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dextroamphetaminechlorpromazine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, dextroamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dextromoramidedextromoramide and chlorpromazine both increase sedation. Use Caution/Monitor.diamorphinediamorphine and chlorpromazine both increase sedation. Use Caution/Monitor.diazepamdiazepam and chlorpromazine both increase sedation. Use Caution/Monitor.dicyclominedicyclomine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.dicyclomine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropionchlorpromazine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, diethylpropion. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.difelikefalindifelikefalin and chlorpromazine both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and chlorpromazine both increase sedation. Use Caution/Monitor.dimenhydrinatedimenhydrinate and chlorpromazine both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and chlorpromazine both increase sedation. Use Caution/Monitor.diphenhydramine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.diphenhydramine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diphenoxylate hcldiphenoxylate hcl and chlorpromazine both increase sedation. Use Caution/Monitor.dipipanonedipipanone and chlorpromazine both increase sedation. Use Caution/Monitor.dobutaminechlorpromazine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, dobutamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dolasetronchlorpromazine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezil transdermaldonepezil transdermal, chlorpromazine. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dopaminechlorpromazine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, dopamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.dopexaminechlorpromazine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinchlorpromazine and dosulepin both increase sedation. Use Caution/Monitor.doxepinchlorpromazine and doxepin both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and chlorpromazine both increase sedation. Use Caution/Monitor.droperidolchlorpromazine and droperidol both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and droperidol both increase sedation. Use Caution/Monitor.eliglustateliglustat increases levels of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.eluxadolinechlorpromazine increases levels of eluxadoline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2D6 inhibitors.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.ephedrinechlorpromazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.epinephrinechlorpromazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.chlorpromazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.epinephrine racemicchlorpromazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.esketamine intranasalesketamine intranasal, chlorpromazine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.estazolamestazolam and chlorpromazine both increase sedation. Use Caution/Monitor.ethanolchlorpromazine and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and chlorpromazine both increase sedation. Use Caution/Monitor.ezogabineezogabine, chlorpromazine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibfedratinib will increase the level or effect of chlorpromazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fenfluraminechlorpromazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.fesoterodinefesoterodine decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.fesoterodine decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flavoxateflavoxate decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.flavoxate decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flecainidechlorpromazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.floxuridinefloxuridine and chlorpromazine both increase QTc interval. Use Caution/Monitor.fluoxetinechlorpromazine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinechlorpromazine and fluphenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.chlorpromazine and fluphenazine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and chlorpromazine both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine and chlorpromazine both increase QTc interval. Modify Therapy/Monitor Closely.formoterolchlorpromazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.foscarnetchlorpromazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fostemsavirchlorpromazine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. ganaxolonechlorpromazine and ganaxolone both increase sedation. Use Caution/Monitor.gemtuzumabchlorpromazine and gemtuzumab both increase QTc interval. Use Caution/Monitor.glycopyrrolatechlorpromazine increases toxicity of glycopyrrolate by unknown mechanism. Use Caution/Monitor.chlorpromazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrrolate inhaledglycopyrrolate inhaled decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.glycopyrrolate inhaled decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.chlorpromazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.chlorpromazine increases toxicity of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.glycopyrronium